PriceTargets.com logo

MEI Pharma - MEIP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.00
  • Forecasted Upside: 115.38%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.25 As of 04/19/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for MEIP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MEI Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEIP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEIP

Analyst Price Target is $7.00
▲ +115.38% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MEI Pharma in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 115.38% upside from the last price of $3.25.

This chart shows the closing price for MEIP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in MEI Pharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2024Stifel NicolausReiterated RatingHold ➝ Hold$7.00Low
2/14/2024Stifel NicolausLower TargetHold ➝ Hold$8.00 ➝ $7.00Low
9/27/2023Stifel NicolausLower TargetHold ➝ Hold$10.00 ➝ $9.00Low
2/24/2023Piper SandlerDowngradeOverweight ➝ NeutralLow
2/13/2023HC WainwrightLower TargetBuy$100.00 ➝ $40.00Low
2/8/2023Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
12/6/2022Truist FinancialDowngradeBuy ➝ HoldLow
12/6/2022BTIG ResearchDowngradeBuy ➝ NeutralLow
11/17/2022BTIG ResearchLower Target$40.00Low
9/12/2022HC WainwrightReiterated RatingBuyLow
5/24/2022BTIG ResearchLower TargetNA$60.00Medium
4/20/2022Alliance Global PartnersLower Target$180.00 ➝ $100.00Medium
3/25/2022BTIG ResearchLower TargetBuy$220.00 ➝ $80.00High
3/25/2022Truist FinancialLower TargetBuy$160.00 ➝ $60.00High
3/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$260.00 ➝ $40.00High
3/25/2022HC WainwrightLower TargetBuy$200.00 ➝ $100.00High
3/25/2022Stifel NicolausDowngradeBuy ➝ Hold$120.00 ➝ $40.00High
3/25/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$80.00 ➝ $20.00High
2/15/2022HC WainwrightReiterated RatingBuy$200.00Medium
2/3/2022Jefferies Financial GroupInitiated CoverageBuy$80.00High
9/9/2021Truist FinancialLower TargetBuy$240.00 ➝ $160.00High
9/7/2021RoweBoost TargetPositive ➝ Buy$230.00 ➝ $400.00High
9/5/2021BTIG ResearchReiterated RatingBuy$180.00Medium
9/3/2021HC WainwrightReiterated RatingBuy$200.00Medium
6/13/2021BTIG ResearchReiterated RatingBuy$110.00Medium
2/8/2021HC WainwrightReiterated RatingBuy$200.00High
10/21/2020Lifesci CapitalReiterated RatingOutperformMedium
10/12/2020Brookline Capital ManagementReiterated RatingBuyMedium
9/22/2020Alliance Global PartnersInitiated CoverageBuy$180.00Medium
7/6/2020SunTrust BanksLower Target$320.00 ➝ $240.00High
7/5/2020Ci CapitalReiterated RatingBuy$180.00High
6/22/2020Ci CapitalReiterated RatingBuy$180.00High
6/14/2020Wells Fargo & CompanyReiterated RatingOverweight ➝ Market Perform$260.00High
5/29/2020SunTrust BanksInitiated CoverageBuy$320.00High
4/14/2020Wells Fargo & CompanyBoost TargetOverweight$220.00 ➝ $260.00High
2/10/2020HC WainwrightReiterated RatingBuy$200.00Low
6/24/2019HC WainwrightReiterated RatingBuy$200.00Low
6/7/2019HC WainwrightReiterated RatingBuy$200.00Low
5/10/2019HC WainwrightReiterated RatingBuyHigh
(Data available from 4/20/2019 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/23/2023
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/21/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/20/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
MEI Pharma logo
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $3.25
Low: $3.22
High: $3.30

50 Day Range

MA: $3.95
Low: $3.19
High: $4.89

52 Week Range

Now: $3.25
Low: $3.20
High: $7.97

Volume

26,402 shs

Average Volume

23,334 shs

Market Capitalization

$21.65 million

P/E Ratio

1.09

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of MEI Pharma?

The following Wall Street sell-side analysts have issued reports on MEI Pharma in the last twelve months: Stifel Nicolaus, StockNews.com, and TheStreet.
View the latest analyst ratings for MEIP.

What is the current price target for MEI Pharma?

1 Wall Street analysts have set twelve-month price targets for MEI Pharma in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 115.4%. Stifel Nicolaus has the highest price target set, predicting MEIP will reach $7.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $7.00 for MEI Pharma in the next year.
View the latest price targets for MEIP.

What is the current consensus analyst rating for MEI Pharma?

MEI Pharma currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MEIP, but not buy more shares or sell existing shares.
View the latest ratings for MEIP.

What other companies compete with MEI Pharma?

Other companies that are similar to MEI Pharma include Synlogic, Onconova Therapeutics, Yumanity Therapeutics, Lumos Pharma and Cumberland Pharmaceuticals. Learn More about companies similar to MEI Pharma.

How do I contact MEI Pharma's investor relations team?

MEI Pharma's physical mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company's listed phone number is (858) 369-7100 and its investor relations email address is [email protected]. The official website for MEI Pharma is www.meipharma.com. Learn More about contacing MEI Pharma investor relations.